Document Detail

The renin inhibitor aliskiren as novel treatment for cardiovascular disease.
MedLine Citation:
PMID:  18221088     Owner:  NLM     Status:  MEDLINE    
The renin-angiotensin aldosterone system (RAAS) plays a key role in the regulation of blood pressure, acting via the effects of the hormone angiotensin (Ang) II. Ang II increases blood pressure and can exert growth-promoting effects leading to end-organ damage. Excess RAAS activity has been shown to be a major underlying cause of hypertension, heart failure, and related cardiovascular disorders. Inhibitors of renin block the RAAS at its first and rate-limiting step and thus appear to offer an excellent opportunity for blood pressure control. In the past two decades various potential renin inhibitors have been developed but have not been clinically useful. This review discusses a recent patent in the development of a novel class of non-peptide renin inhibitors: an alkanecarboxamide, aliskiren (SPP-100; Novartis). Aliskiren is effective in animal models, while recent results from studies in humans indicate that aliskiren is the first in a new class of orally effective renin inhibitors for the treatment of hypertension.
Anabelle O Saez; Thomas Philipp; Jens Nürnberger
Related Documents :
8860098 - Parathyroid hypertensive factor predicts efficacy in the treatment of essential hyperte...
3744468 - Peripheral pressor systems in hypertension caused by nucleus tractus solitarius lesions.
20375118 - The ang-(1-7)/ace2/mas axis in the regulation of nephron function.
2228158 - Pressor systems in hypertension and congestive heart failure. role of vasopressin.
11868598 - Water intake and 24-hour blood pressure monitoring in a patient with nephrogenic diabet...
10658278 - Assessment of fetal heart rate variability and velocity variability by doppler velocime...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Recent patents on cardiovascular drug discovery     Volume:  1     ISSN:  1574-8901     ISO Abbreviation:  Recent Pat Cardiovasc Drug Discov     Publication Date:  2006 Nov 
Date Detail:
Created Date:  2008-01-28     Completed Date:  2008-02-15     Revised Date:  2011-11-22    
Medline Journal Info:
Nlm Unique ID:  101263805     Medline TA:  Recent Pat Cardiovasc Drug Discov     Country:  United Arab Emirates    
Other Details:
Languages:  eng     Pagination:  233-40     Citation Subset:  IM    
Department of Nephrology and Hypertension, University Hospital Essen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aldosterone Antagonists / therapeutic use
Amides / pharmacology,  therapeutic use*
Angiotensin II Type 1 Receptor Blockers / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Antihypertensive Agents / therapeutic use*
Blood Pressure
Drug Therapy, Combination
Fumarates / pharmacology,  therapeutic use*
Hypertension / drug therapy*
Renin / antagonists & inhibitors*
Renin-Angiotensin System / drug effects,  physiology
Reg. No./Substance:
0/Aldosterone Antagonists; 0/Amides; 0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Fumarates; 0/aliskiren; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Fibroblast growth factors, fibroblast growth factor receptors, diseases, and drugs.
Next Document:  TP receptor as a therapeutic target in atherosclerosis and related cardiovascular diseases.